

# Adjuvant 5-fluorouracil and folinic acid vs observation data from the ESPAC-1 and -3(v1) trials

British Journal of Cancer

100, 246-250

DOI: [10.1038/sj.bjc.6604838](https://doi.org/10.1038/sj.bjc.6604838)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pancreatic cancer: advances in medical therapy. Expert Review of Clinical Pharmacology, 2009, 2, 173-180.	1.3	0
2	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5513-5518.	0.8	708
3	A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. British Journal of Cancer, 2009, 101, 908-915.	2.9	385
4	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 185-189.	1.0	1
5	Pancreatic surgery. Current Opinion in Gastroenterology, 2009, 25, 460-465.	1.0	6
6	Analog of Vitamin E Epitomized by Î±-Tocopheryl Succinate for Pancreatic Cancer Treatment. Pancreas, 2010, 39, 662-668.	0.5	9
7	A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer. Annals of Surgical Oncology, 2010, 17, 194-205.	0.7	136
8	Sociodemographics and Comorbidities Influence Decisions to Undergo Pancreatic Resection for Neoplastic Lesions. Journal of Gastrointestinal Surgery, 2010, 14, 1401-1408.	0.9	13
9	Pilot study of irinotecan/oxaliplatin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Investigational New Drugs, 2010, 28, 343-349.	1.2	15
10	Progress for resectable cancer?. Cancer, 2010, 116, 1681-1690.	2.0	49
12	Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. Hpb, 2010, 12, 447-455.	0.1	58
14	Deploying Mouse Models of Pancreatic Cancer for Chemoprevention Studies. Cancer Prevention Research, 2010, 3, 1382-1387.	0.7	27
15	Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 529-540.	1.1	37
16	Adjuvant therapy of pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 485-491.	1.1	4
17	Adjuvant Therapy in Pancreatic Cancer. Digestive Diseases, 2010, 28, 684-692.	0.8	24
18	Update on Adjuvant Trials for Pancreatic Cancer. Surgical Oncology Clinics of North America, 2010, 19, 391-409.	0.6	4
19	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
20	Adjuvant Chemoradiation Therapy for Pancreas Cancer: Who Really Benefits?. Advances in Surgery, 2010, 44, 149-164.	0.6	4

#	ARTICLE	IF	CITATIONS
21	Prognostic Implications of Intraoperative Radiotherapy for Unresectable Pancreatic Cancer. <i>Pancreatology</i> , 2011, 11, 68-75.	0.5	10
22	Acinar cell carcinoma of the pancreas: is resection justified even in limited metastatic disease?. <i>American Journal of Surgery</i> , 2011, 202, 23-27.	0.9	50
23	Adjuvant treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2011, 47, S378-S380.	1.3	25
24	Impact of dihydropyrimidine dehydrogenase and $\hat{1}^3$ -glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 1097-1103.	0.8	12
25	Randomized trials in exocrine pancreatic cancer. <i>Przegląd Gastroenterologiczny</i> , 2011, 2, 85-96.	0.3	1
26	Clinical Potential of MicroRNAs in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2011, 40, 1165-1171.	0.5	42
27	Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages. <i>International Journal of Oncology</i> , 2012, 40, 427-35.	1.4	0
28	Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results. <i>Surgical Oncology</i> , 2011, 20, e161-e168.	0.8	20
29	Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 1122-1129.	0.7	24
30	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. <i>Molecular Cancer</i> , 2011, 10, 37.	7.9	200
31	Pancreatic Cancer Surgery in the New Millennium. <i>Annals of Surgery</i> , 2011, 254, 311-319.	2.1	367
32	Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2011, 12, 5895-5907.	1.8	12
33	Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 118.	0.5	67
34	Progress in pancreatic cancer: moving beyond gemcitabine?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 997-1000.	1.1	1
35	The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 469-480.	1.1	10
36	CXCR4 Expression Predicts Early Liver Recurrence and Poor Survival After Resection of Pancreatic Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e22.	1.3	15
37	Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas. <i>Current Drug Targets</i> , 2012, 13, 781-788.	1.0	12
38	Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer. <i>Current Drug Targets</i> , 2012, 13, 789-794.	1.0	2

#	ARTICLE	IF	CITATIONS
39	Age and pancreaticoduodenectomy: is it really about mortality?. <i>Hpb</i> , 2012, 14, 647-648.	0.1	1
40	Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e507-e511.	0.4	25
41	Protonation Preferentially Stabilizes Minor Tautomers of the Halouracils: IRMPD Action Spectroscopy and Theoretical Studies. <i>Journal of the American Society for Mass Spectrometry</i> , 2012, 23, 1469-1478.	1.2	30
42	Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). <i>Gastroenterology Clinics of North America</i> , 2012, 41, 189-209.	1.0	31
43	Pancreatic adenocarcinoma: Outstanding problems. <i>World Journal of Gastrointestinal Surgery</i> , 2012, 4, 104.	0.8	40
44	Improving survival following surgery for pancreatic ductal adenocarcinoma – A ten-year experience. <i>European Journal of Surgical Oncology</i> , 2012, 38, 245-251.	0.5	23
45	Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2012, 38, 333-339.	0.5	59
46	Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. <i>BMC Cancer</i> , 2012, 12, 226.	1.1	41
47	New biomarkers and targets in pancreatic cancer and their application to treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 435-444.	8.2	194
48	Impact of Radiation Therapy Sequence on Survival Among Patients With Resected Pancreatic Head Ductal Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 26-30.	0.7	5
49	Drugs in preclinical and early-stage clinical development for pancreatic cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 143-152.	1.9	28
51	Current Knowledge on Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 6.	1.3	62
52	Long-term changes in body composition after pancreaticoduodenectomy. <i>ANZ Journal of Surgery</i> , 2012, 82, 173-178.	0.3	9
53	Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 Tj ETQq1 1 0.784314 rgBT /Overl cancer - NEOPANC. <i>BMC Cancer</i> , 2012, 12, 112.	1.1	12
54	Pre-operative cardiopulmonary exercise testing predicts adverse post-operative events and non-progression to adjuvant therapy after major pancreatic surgery. <i>Hpb</i> , 2013, 15, 899-907.	0.1	49
55	Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. <i>BMC Surgery</i> , 2013, 13, 12.	0.6	48
56	Impact of Adjuvant Radiotherapy on Survival after Pancreatic Cancer Resection: An Appraisal of Data from the National Cancer Data Base. <i>Annals of Surgical Oncology</i> , 2013, 20, 3634-3642.	0.7	75
57	Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?. <i>Hpb</i> , 2013, 15, 872-881.	0.1	17

#	ARTICLE	IF	CITATIONS
58	Improvement of surgical results for pancreatic cancer. <i>Lancet Oncology</i> , The, 2013, 14, e476-e485.	5.1	307
59	Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas â€“ A retrospective tumor marker prognostic study. <i>International Journal of Surgery</i> , 2013, 11, 1067-1072.	1.1	88
60	Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1095-1103.	5.1	198
61	Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp<sup>âˆ’âˆ’</sup>/rag2<sup>âˆ’âˆ’</sup> mice. <i>Gut</i> , 2013, 62, 741-750.	6.1	48
62	Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patientsâ€™ quality of life. <i>World Journal of Surgical Oncology</i> , 2013, 11, 3.	0.8	7
63	Adjuvant therapy for pancreas adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 78-85.	0.8	13
64	Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. <i>Gastrointestinal Tumors</i> , 2014, 1, 41-52.	0.3	16
65	Diagnosis and management of pancreatic cancer. <i>Cmaj</i> , 2013, 185, 1219-1226.	0.9	68
66	Surgical management in patients with pancreatic cancer: a <scp>Q</scp>ueensland perspective. <i>ANZ Journal of Surgery</i> , 2013, 83, 859-864.	0.3	6
67	Pancreatic and ovarian cancer biomarkers. , 2014, , 759-770.		1
68	Precursor Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	150
70	Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 59-65.	2.0	61
71	Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens. <i>International Journal of Clinical Practice</i> , 2014, 68, 578-589.	0.8	4
72	A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma. <i>Annals of Surgery</i> , 2014, 260, 142-148.	2.1	121
73	Prognostic significance of pre-operative C-reactive protein and the neutrophilâ€“lymphocyte ratio in resectable pancreatic cancer: a systematic review. <i>Hpb</i> , 2015, 17, 285-291.	0.1	75
74	Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature. <i>Oncology Letters</i> , 2015, 10, 263-267.	0.8	8
75	Biomarkers for early diagnosis of pancreatic cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 305-315.	1.4	36
76	Advances in Chemotherapy for Pancreatic Cancer. <i>Indian Journal of Surgical Oncology</i> , 2015, 6, 47-56.	0.3	5

#	ARTICLE	IF	CITATIONS
77	Pancreatic cancer: Patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. <i>Pancreatology</i> , 2015, 15, 701-707.	0.5	32
78	Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 149.	0.8	3
80	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	12.5	489
81	Adjuvant vs. salvage radiotherapy for patients at high risk for recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 451-455.	0.8	4
82	Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1229-1237.	0.7	24
83	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. <i>Pancreatology</i> , 2015, 15, 8-18.	0.5	404
84	Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma. <i>British Journal of Surgery</i> , 2016, 103, 1200-1208.	0.1	21
85	Clinical Decision-Making in Pancreatic Cancer. , 2016, , 1-32.		0
86	A pancreatic cancer multidisciplinary clinic: insights and outcomes. <i>Journal of Surgical Research</i> , 2016, 202, 246-252.	0.8	16
87	The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 115, 887-894.	2.9	48
88	Systemic Therapy in Pancreatic Cancer. , 2016, , 247-273.		1
89	Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. <i>Gastroenterology</i> , 2016, 151, 338-350.e7.	0.6	65
90	Meta-analyses of treatment standards for pancreatic cancer. <i>Molecular and Clinical Oncology</i> , 2016, 4, 315-325.	0.4	31
91	Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?. <i>Journal of the American College of Surgeons</i> , 2016, 222, 448-456.	0.2	50
92	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 14-27.	0.5	81
93	The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. <i>Scandinavian Journal of Surgery</i> , 2017, 106, 54-61.	1.3	43
94	Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1731-1738.	0.7	20
95	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 1011-1024.	6.3	1,475

#	ARTICLE	IF	CITATIONS
96	Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. <i>Drug Discovery Today</i> , 2017, 22, 690-701.	3.2	27
97	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. <i>Gut</i> , 2017, 66, 1665-1676.	6.1	212
98	Oncolytic viral therapy for pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 94-103.	0.8	34
99	Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma. <i>Hpb</i> , 2017, 19, 1046-1057.	0.1	26
100	Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. <i>Oncology Letters</i> , 2017, 14, 1505-1511.	0.8	7
101	Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection. <i>Digestive Surgery</i> , 2017, 34, 125-132.	0.6	13
102	Chemotherapy and radiotherapy for pancreatic cancer. , 2017, , 1032-1041.e3.		0
103	Surgical Outcomes of Pancreaticoduodenectomy for Pancreatic Cancer with Proximal Dorsal Jejunal Vein Involvement. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1179-1185.	0.9	15
104	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , 2018, 118, 947-954.	2.9	30
105	BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2018, 226, 630-637.e1.	0.2	62
106	Clinical Decision-Making in Pancreatic Cancer. , 2018, , 601-632.		0
107	Adjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1039-1071.		0
108	Development of Novel Therapeutic Response Biomarkers. , 2018, , 1273-1304.		0
109	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2018, 118, 1084-1088.	2.9	9
110	Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies. <i>Surgical Clinics of North America</i> , 2018, 98, 95-111.	0.5	25
111	Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 917-932.	0.8	67
112	Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. <i>Cancer Management and Research</i> , 2018, Volume 10, 4065-4072.	0.9	7
113	Adjuvant Treatment in Potentially Curable Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, e50-e52.	0.5	4

#	ARTICLE	IF	CITATIONS
114	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. <i>Advances in Surgery</i> , 2019, 53, 253-269.	0.6	4
115	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. <i>Cancers</i> , 2019, 11, 1547.	1.7	10
116	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987556.	1.4	144
117	Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?. <i>Cancers</i> , 2019, 11, 1621.	1.7	5
118	Environmental Risk Factors of Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1427.	1.0	35
119	Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4543.	1.8	68
120	Adjuvant treatment for pancreatic cancer. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 27-27.	1.5	44
122	“Laparoscopic Para-Aortic Lymph Node Sampling”-First Approach for Pancreatic Adenocarcinoma as an Oncological Practice. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 900-904.	0.5	4
123	Extracellular and intracellular microRNAs in pancreatic cancer: from early diagnosis to reducing chemoresistance. <i>ExRNA</i> , 2019, 1, .	1.0	4
124	Impact of Immunotherapy after Resection of Pancreatic Cancer. <i>Journal of the American College of Surgeons</i> , 2019, 229, 19-27.e1.	0.2	11
125	Advances in the Treatment of Pancreatic Cancer. , 2019, , .		1
126	Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. <i>BMJ Open</i> , 2019, 9, e028696.	0.8	3
127	Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. <i>Medicine (United States)</i> , 2019, 98, e15064.	0.4	8
128	Adjuvant treatment of pancreatic cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 346-353.	1.1	23
129	Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. <i>Journal of Controlled Release</i> , 2019, 293, 21-35.	4.8	42
130	Optimizing the outcomes of pancreatic cancer surgery. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 11-26.	12.5	546
131	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 520-529.	2.1	189
132	Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102817.	2.0	21



#	ARTICLE	IF	CITATIONS
133	A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC). <i>Hpb</i> , 2020, 22, 649-659.	0.1	15
134	Commentary: Neoadjuvant treatment of resectable pancreatic cancer: Lack of level III evidence. <i>Surgery</i> , 2020, 168, 1015-1016.	1.0	8
135	The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. <i>Scientific Reports</i> , 2020, 10, 12004.	1.6	6
136	Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life. <i>Anticancer Research</i> , 2020, 40, 6997-7001.	0.5	7
137	Identification and Validation of Circulating Micrnas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. <i>Journal of Clinical Medicine</i> , 2020, 9, 2440.	1.0	11
138	Oncologic Impact of Local Recurrence in Resected Pancreatic Cancer and Topographic Preference in Local Recurrence Patterns According to Tumor Location. <i>Pancreas</i> , 2020, 49, 1290-1296.	0.5	5
139	Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes, and Risk Factors. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1581-1589.	0.9	29
140	Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy. <i>Cancer Imaging</i> , 2020, 20, 22.	1.2	5
141	Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data. <i>BMC Public Health</i> , 2020, 20, 1002.	1.2	1
142	Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based study. <i>Pancreatology</i> , 2020, 20, 454-461.	0.5	18
143	Small molecule inhibitors in pancreatic cancer. <i>RSC Medicinal Chemistry</i> , 2020, 11, 164-183.	1.7	21
144	Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. <i>Journal of Pancreatology</i> , 2020, 3, 1-11.	0.3	13
145	Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	1.0	5
147	The Evolution of Adjuvant Trials in Pancreatic Cancer. , 2021, , 743-761.		1
148	Seminars in surgical oncologyâ€”Pancreas cancer adjuvant therapy trials. <i>Journal of Surgical Oncology</i> , 2021, 123, 1467-1474.	0.8	1
149	Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2021, 11, 7499.	1.6	10
151	A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 650266.	1.3	6
152	The importance of timeâ€”toâ€”adjuvant treatment on survival with pancreatic cancer: A systematic review and metaâ€”analysis. <i>Cancer Reports</i> , 2021, 4, e1390.	0.6	4

#	ARTICLE	IF	CITATIONS
153	Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 376-386.	0.9	4
155	Neoadjuvant treatment of localized pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 0-0.	0.6	1
156	Adjuvant Chemotherapy in Pancreatic Cancer. , 2010, , 1051-1077.		2
157	Chemotherapy and radiotherapy for pancreatic and periampullary cancer. , 2012, , 972-978.e2.		1
158	Carcinoembryonic Antigen-Related Cell Adhesion Molecules (CEACAM) 1, 5 and 6 as Biomarkers in Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e113023.	1.1	76
159	Locally-applied 5-fluorouracil-loaded slow-release patch prevents pancreatic cancer growth in an orthotopic mouse model. <i>Oncotarget</i> , 2017, 8, 40140-40151.	0.8	18
160	Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. <i>Oncotarget</i> , 2017, 8, 81419-81429.	0.8	13
161	Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Biomarkers in Pancreatic Cancer. <i>Current Genomics</i> , 2020, 20, 569-580.	0.7	17
162	Pancreatic cancer: Translational research aspects and clinical implications. <i>World Journal of Gastroenterology</i> , 2012, 18, 1417.	1.4	23
163	Adjuvant and neoadjuvant treatment in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2012, 18, 1565.	1.4	46
164	Personalising pancreas cancer treatment: When tissue is the issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7849.	1.4	22
165	Adjuvant therapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 14733.	1.4	36
166	Evolving treatment landscape for early and advanced pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 281.	0.8	26
167	The European Study Group for Pancreatic Cancer (ESPAC) Trials. , 2010, , 109-121.		0
169	Pankreaskarzinom und periampulläre Karzinome. , 2010, , 563-586.		3
170	Multimodality Management of Localized and Borderline Resectable Pancreatic Adenocarcinoma. , 2011, , 173-203.		0
171	Adjuvant trials for pancreatic cancer: where are we going and what is needed?. <i>Clinical Investigation</i> , 2011, 1, 651-667.	0.0	0
173	Adjuvant Chemotherapy in Pancreatic Cancer. , 2016, , 1-34.		0

#	ARTICLE	IF	CITATIONS
174	Development of Novel Therapeutic Response Biomarkers. , 2017, , 1-32.		0
176	Surgery with adjuvant or neoadjuvant treatment vs surgery alone for resectable pancreatic cancer: A network meta-analysis. World Journal of Meta-analysis, 2019, 7, 309-322.	0.1	0
177	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2021, , 1-22.		0
178	Impact of Acute Inflammation on the Survival Outcomes of Patients with Resected Pancreatic Ductal Adenocarcinoma. Digestive Surgery, 2021, 38, 343-351.	0.6	1
179	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S43-7.	0.8	2
180	Accomplishments in 2008 in the management of localized pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S37-42.	0.8	2
181	Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Gastrointestinal Cancer Research: GCR, 2013, 6, 115-7.	0.8	0
182	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	1.7	5
183	Chirurgische Therapie des Pankreaskarzinoms. , 2015, , 1-9.		0
184	Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. JAMA Oncology, 2022, 8, 88.	3.4	11
185	Early discontinuation of adjuvant chemotherapy in patients with early-stage pancreatic cancer correlates with inferior survival: A multicenter population-based cohort study. PLoS ONE, 2022, 17, e0263250.	1.1	2
186	Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma. American Journal of Surgical Pathology, 2022, 46, 754-764.	2.1	20
188	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2022, , 535-556.		0
190	Management of Resectable and Borderline Resectable Disease: Medical Oncology. , 2022, , 139-151.		0
191	Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. Current Issues in Molecular Biology, 2023, 45, 1914-1949.	1.0	2